Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2023-03-21
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA
NCT03988309
UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study
NCT05893316
New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease
NCT02250287
Efficacy and Utility of Cxbladder Tests in Hematuria Patients
NCT04943380
Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer
NCT00975455
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Firefighters who receive multi-cancer early detection (MCED) test
MCED
multi-cancer early detection (MCED) test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MCED
multi-cancer early detection (MCED) test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently employed as a firefighter, full-time or part-time
* Taking part in Vincere's First Responder Cancer Screening Program
* Able to donate blood and urine sample
* Able to provide informed consent to participate in the study
Exclusion Criteria
* Personal history of cancer in the last 5 years (with the exception of non-melanoma skin cancer)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Elypta
INDUSTRY
Proteotype
UNKNOWN
Vincere Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vershalee Shukla, MD
Role: PRINCIPAL_INVESTIGATOR
Vincere Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vincere Cancer Center
Scottsdale, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VCC-MCEDFF-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.